суббота, 25 июня 2016 г.

Brexit spells upheaval for EU and UK drug regulation

Brexit spells upheaval for EU and UK drug regulation


Britain's vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency , which approves treatments for all EU countries, expected to have to relocate. The association of Germany's pharmaceuticals industry said on Friday that Europe's equivalent of the U.S. Food and Drug Administration would need to move to a city within the EU, bringing administrative headaches for companies.



from Biotech News